Nuvectis Pharma, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-26.4M | $-19.0M | $-22.3M | $-19.1M | $-12.9M |
| Depreciation & Amortization | — | — | — | — | — |
| Depreciation | — | — | — | — | — |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $6.0M | $4.9M | $4.7M | $1.7M | $1.9M |
| Net Cash from Operating Activities | $-16.0M | $-12.2M | $-16.0M | $-13.6M | $-9.5M |
| Investing Activities | |||||
| Capital Expenditures | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | — | $0 | $0 | $0 | — |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | $29.1M | $11.7M | $15.1M | $27.8M | $15.2M |
| Net Change in Cash | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |